Efficacy Of Rebamipide In The Treatment Of NSAIDs-related Gastrointestinal Adverse Reactions:A Meta-analysis

Objective:To evaluate the efficacy of Rebamipide in the treatment of NSAIDs-related gastrointestinal adverse reactions.Methods : The Cochrane Library,PubMed database,Medline,EMBASE,Chinese Biomedical Literature Database(CBM),China National Knowledge Infrastructure(CNKI)database and WanFang Data were searched for randomized controlled trials of Rebamipide in the treatment of NSAIDs-related gastrointestinal adverse reactions.Two reviewers assessed the quality of included literature and extracted dataindependently.Meta-analysis was carried out by the RevMan software5.3.Results: 11 trials involving 466 individuals,138 healthy volunteers were included.Meta-analysis showed that rebamipide was significantly better than placebo in terms of NSAIDs-related gastrointestinal symptoms(OR=0.34,95% CI: 0.19-0.58);there was no significant difference between rebamipide and placebo In the mild gastric mucosal injury caused by NSAIDs(OR = 1.29,95% CI: 0.29~4.30);however,rebamipide can produce effective protection in terms of NSAIDs-related severe gastric mucosal injury(OR = 0.19,95% CI: 0.08 ~ 0.44)and moderate to severe intestinal mucosal damage(erosive(MD=-3.42,95% CI:-4.84 ~-2.00),ulcer(MD=-0.47,95)%CI:-0.92 to-0.01)).Conclusion : Rebapatide can effectively prevent not only thegastrointestinal symptoms but also moderate to severe gastrointestinal mucosal damage caused by NSAIDs.